lrb, your post brought this back to my attention. Looks most interesting, $400M cap, <$120M cash, fairly low burn. Product (niche) in the market; said product in trials for indications that may get it (way) out of the niche. Interesting, if somewhat token, pre-clinical programs.
A number of years ago I listened to a presentation by Howard Jaffee, who ran the Actimmune program at Genentech, and it sounded pretty good. Jaffee went on to run the clinical department at Gilead, not sure where he is now. Perhaps this, Actimmune, was not DNA/GNE-good, but certainly ITMN-$400M-good. As I said elsewhere, it took a while for alpha and beta interferons to find their relatively big market applications; if gamma is next, this may be a good way to play it.
Here are some relevant links for material published in the New England Journal:
Clinical study:
nejm.org
Editorial:
nejm.org
Critical commentary (which may have helped the stock to come down) followed by a reply from the authors of the study above:
nejm.org
Thanks for pointing this out; "good stuff." And still trying to find Rick's socks ...
PB |
